by Admin | Dec 16, 2021 | Portfolio News
MENDHAM, N.J. and WARMINSTER, Pa., December 14, 2021 – Antios Therapeutics, Inc. (“Antios”) and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the first patient has been dosed in a triple combination treatment in patients with chronic hepatitis...
by Admin | Dec 9, 2021 | Portfolio News
Platform combines the innate immuno-stimulatory effect of the myxoma virus with anti-tumor immune stimulation that uniquely target multiple aspects of cancer immunity to treat solid tumors and hematological cancersOncoMyx is developing a next generation oncolytic...
by Admin | Nov 4, 2021 | Portfolio News
– Financing round was co-led by GordonMD Global Investment LP – Funding will support the Phase 2b clinical program of ATI-2173 in HBV MENDHAM, N.J., Nov. 3, 2021 /PRNewswire/ — Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical...
by Admin | Sep 22, 2021 | Portfolio News
三叶草新冠候选疫苗的全球2/3期临床试验结果显示对德尔塔 (Delta) 变异株的保护效力为79% 在全球四大洲的 “ SPECTRA” 2/3期临床试验共入组了超过30,000 名成年和老年受试者,在保护效力分析中100% 的SARS-CoV-2(新冠病毒)均为变异株(Delta变异株为主)临床试验成功达到疫苗保护效力的主要终点及次要终点“...
by Admin | Jul 28, 2021 | Portfolio News
SHANGHAI, July 28, 2021 /PRNewswire/ — Eccogene, Inc., a clinical stage biopharmaceutical company focused on discovery and development of metabolic and immunologic therapeutics, announced the initiation of a Phase 1a clinical trial evaluating ECC0509, an oral...
by Admin | Jul 16, 2021 | Portfolio News
Imperative Care to Create Strategic Network of Wholly Owned Development Subsidiaries in Areas of Synergy, Starting with Acquisition of Truvic Medical, Inc., a Peripheral Thrombectomy Innovator July 15, 2021 08:00 AM Eastern Daylight Time CAMPBELL,...